贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的效果观察

Efficacy of bevacizumab combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

目的 探讨贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的效果及安全性。方法 选取2017年8月至2020年8月间茂名市人民医院收治的83例局部晚期宫颈癌患者,按照治疗方法的不同将患者分为对照组和研究组,采用同步放化疗治疗的41例患者纳入对照组,采用贝伐珠单抗联合同步放化疗治疗的42例患者纳入研究组。比较两组患者近远期治疗疗效、治疗前后的肿瘤直径以及不良反应。结果 两组1年总生存率和无瘤生存率比较,差异无统计学意义(P>0.05);研究组3年、5年总生存率和无瘤生存率均高于对照组,差异均有统计学意义(均P<0.05)。治疗后两组肿瘤直径缩小,且研究组比对照组明显,差异均有统计学意义(均P<0.05)。两组血红蛋白下降、白细胞下降、血小板下降、肝功能异常、肾功能异常、放射性膀胱炎、放射性直肠炎和皮炎等不良反应比较,差异无统计学意义(P>0.05)。结论 贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌,可有效缩小肿瘤直径,提高患者的远期总生存率和无瘤生存率,且不会增加不良反应。

Objective To analyze the efficacy and safety of bevacizumab combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer. Methods A total of 83 patients with locally advanced cervical cancer diagnosed and treated at Maoming People’s Hospital from August 2017 to August 2020 were selected. The patients were divided into an experimental group and a control group, 42 patients receiving bevacizumab combined with concurrent radiotherapy and chemotherapy were included in the experimental group and 41 patients receiving concurrent radiotherapy and chemotherapy were included in a control group. The short-term and long-term therapeutic effects, the tumor diameter before and after treatment and adverse reactions were compared between the two groups. Results The 1-year overall survival rate and tumor-free survival rate was not statistically significant between the two groups(P>0.05). The 3-year and 5-year overall survival rate and tumor-free survival rate were significantly higher in the experimental group than those in the control group(all P<0.05). After the treatment, the tumor diameter decreased in the two groups, and the changes was more obvious in the experimental group than in the control group(P<0.05). There was no statistical significance in the adverse reactions such as decrease in hemoglobin, white blood cell and platelet, abnormal liver function and renal function, radiation cystitis, radiation proctitis and dermatitis between the two groups(P>0.05). Conclusion Bevacizumab combined with concurrent radiotherapy and chemotherapy for locally advanced cervical cancer can effectively reduce tumor diameter and improve long-term overall survival and tumor-free survival rate without increasing adverse reactions.